Previous 10 | Next 10 |
SALT LAKE CITY , March 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2019 , and provided a corporate update. Fourth Quarter and Recent Corporate High...
SALT LAKE CITY , Feb. 27, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a registered direct offering of 10,084,034 Class A Units, each consisting of one share...
Lipocine (NASDAQ: LPCN ) -28.4% pre-market after announcing a registered direct offering intended to raise ~$6M. More news on: Lipocine Inc., Healthcare stocks news, Stocks on the move, Read more ...
SALT LAKE CITY , Feb. 25, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into securities purchase agreements with certain institutional investors providing for...
List Of Penny Stocks To Watch Making Bigger Moves Right now While some may avoid penny stocks because they don’t understand risk, others jump headfirst. But why? For the most part, someone trading penny stocks enjoys volatility. With that comes greater levels of riskiness. Where you c...
Lipocine ( LPCN +38.3% ) jumps to three-month highs after saying the Food and Drug Administration indicated the company's approach to addressing the single remaining deficiency in its New Drug Application for oral testosterone product candidate Tlando appears to be a reasonable path forwa...
SALT LAKE CITY , Feb. 24, 2020 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the results of its Post Action meeting with the U.S. Food and Drug Administration ("FDA') regarding its New Dr...
SALT LAKE CITY , Feb. 11, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, announced today that in an effort to streamline the issues and associated costs for dispute in its infringement lawsuit against Clarus Therapeutics, Inc. ("Clarus"...
Every once in a while I like to check oversold stocks to find good stocks to buy. Since stocks generally move in cycles with a high peak and a low trough, an investor could just buy low and sell high. But some stocks stay oversold for long periods of time and may have a long term downward tren...
Shares of Lipocine Inc. (NASDAQ:LPCN) traded at a new 52-week low today of $0.34. So far today approximately 414,000 shares have been exchanged, as compared to an average 30-day volume of 993,000 shares. Lipocine Inc. has overhead space with shares priced $0.35, or 80.3% below the average con...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...